In a report released today, Matthew O’Brien from Piper Sandler reiterated a Buy rating on PROCEPT BioRobotics (PRCT – Research Report), with a price target of $42.00. The company’s shares closed yesterday at $42.21.
According to TipRanks, O’Brien is a 5-star analyst with an average return of 7.1% and a 52.86% success rate. O’Brien covers the Healthcare sector, focusing on stocks such as Medtronic, Alphatec Holdings, and Atricure.
Currently, the analyst consensus on PROCEPT BioRobotics is a Strong Buy with an average price target of $47.57, which is a 12.70% upside from current levels. In a report released yesterday, Wells Fargo also maintained a Buy rating on the stock with a $47.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $43.90 and a one-year low of $24.83. Currently, PROCEPT BioRobotics has an average volume of 496.1K.
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PRCT in relation to earlier this year. Most recently, in October 2023, Reza Zadno, the President & CEO of PRCT bought 5,148.00 shares for a total of $22,496.76.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PROCEPT BioRobotics (PRCT) Company Description:
PROCEPT BioRobotics Corp is a commercial-stage surgical robotics company focused on advancing patient care by developing transformative solutions in urology.
Read More on PRCT:
